Jan Astermark
21 – 40 of 179
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children : A critical review from the physician's perspective
(
- Contribution to journal › Scientific review
-
Mark
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81–8973
(
- Contribution to journal › Article
-
Mark
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins : Real-world experience in the Nordic countries
(
- Contribution to journal › Article
-
Mark
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
(
- Contribution to journal › Article
-
Mark
Autologous cell therapy - A new concept to eradicate inhibitors in haemophilia
(
- Contribution to journal › Letter
-
Mark
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B : Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
(
- Contribution to journal › Article
-
Mark
New Inhibitors in the Ageing Population : A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
(
- Contribution to journal › Article
- 2021
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
(
- Contribution to journal › Article
-
Mark
Identification of F8 rearrangements in carrier and non-carrier mothers of haemophilia A patients
(
- Contribution to journal › Letter
-
Mark
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in elective non-orthopaedic surgery of adults with haemophilia and inhibitors : A systematic literature review
(
- Contribution to journal › Scientific review
-
Mark
Treatment outcomes in persons with severe haemophilia B in the Nordic region : The B-NORD study
(
- Contribution to journal › Article
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
(
- Contribution to journal › Article
-
Mark
Efficacy of rfixfc versus rix-fp for the treatment of patients with hemophilia b : Matching-adjusted indirect comparison of b-long and prolong-9fp trials
(
- Contribution to journal › Article
-
Mark
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
(
- Contribution to journal › Article
-
Mark
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A
(
- Contribution to journal › Article
-
Mark
Droplet digital PCR and mile-post analysis for the detection of F8 int1h inversions
(
- Contribution to journal › Article
-
Mark
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
(
- Contribution to journal › Article